Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?)

Authors

  • James H. Tabibian M.D.,

    1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
    2. Center for Clinical and Translational Sciences, Mayo Clinic, Rochester, MN
    Search for more papers by this author
  • Keith D. Lindor M.D.

    Corresponding author
    1. College of Health Solutions, Arizona State University, Phoenix, AZ
    • Address reprint requests to: Keith D. Lindor, M.D., College of Health Solutions, Arizona State University, 550 North 3rd Street, Phoenix, AZ 85004. E-mail: keith.lindor@asu.edu; fax: 602-496-0544.

    Search for more papers by this author

  • Potential conflict of interest: Nothing to report.

  • See Article on Page 931

  • This work was funded by T32DK007198 (training grant support for J.H.T.) and UL1TR000135 (to the Mayo Clinic Center for Clinical and Translational Science).

Ancillary